On Monday, Merck & Co., Inc. MRK announced a definitive agreement with Cubist Pharmaceuticals CBST under which Merck will acquire Cubist for $102 per share in a transaction with a total value of roughly $9.5 billion.
Cubist was up more than 35 percent Monday morning.
Following the announcement, other pharmaceutical stocks are in play Monday:
Cempra Inc CEMP +6.4 percent
CAS Medical Systems Inc CASM +2.2 percent
Dynavax Technologies Corporation DVAX +0.5 percent
Arena Pharmaceuticals, Inc. ARNA -0.7 percent
VIVUS, Inc. VVUS
Repros Therapeutics Inc RPRX
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
